Responsiveness and minimal clinically important difference in patient-reported outcome measures among patients with psoriatic arthritis.

SRMs and MCII were relatively small in this real-world population, particularly among those with lower disease activity at baseline. BASDAI, cDAPSA and PSAID had good sensitivity to change but selection for use in trials should consider on the baseline disease activity of patients to be enrolled.